The White House has paused plans to impose tariffs on generic drug imports, benefiting Indian pharmaceutical companies and US consumers. India supplies 47% of generics in the US, saving billions in healthcare costs. The decision follows internal debates over tariffs and manufacturing, reaffirmin India's pivotal role in global pharma and the continued importance of affordable medicines.